Problems of medicine provision in dermatovenerology at the present stage

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, the medicine shortage is a global phenomenon that characterizes the imperfection of the organization of medical care throughout the world. It leads to inconvenience for national health care systems, loss of profit for medical and pharmacy institutions, and also poses a risk to patient health due to inadequate, interrupted or insufficient treatment. Against this background, the range of pro-ducts for topical therapy – combined creams and ointments – has sharply decreased in the pharmacy network of the Russian Federation; aerosol forms of combined corticosteroids have also disappeared almost completely. According to expert estimates, satisfaction with the availability and quality of drug care in the Russian Federation in 2022 did not exceed 60–65%. Current problems of drug availability, as well as various aspects of the balance of drug and financial resources cannot be fully resolved by the existing medicine provision system. The current situation creates additional risks of deterioration in the quality of life and condition of people suffering from socially significant diseases, as well as the risk of increased mortality. More than 60% of the pharmaceutical market in the country is currently occupied by drugs produced in Russia. But the vast majority represents analogues of foreign drugs. According to expert estimates, proportion of original drugs, i.e. invented and produced directly in the country, is no more than 13%. At the same time, experts cannot speak unambiguously about the therapeutic equivalence and quality of Russian analogues. Another alternative direction for replenishing the drug shortage, especially for topical use, is to recreate industrial pharmacies.

Full Text

Restricted Access

About the authors

A. A. Martynov

Russian Medical Academy of Continuous Professional Education

Email: avvla@mail.ru
ORCID iD: 0000-0002-5756-2747
SPIN-code: 2613-8597
Russian Federation, Moscow

A. V. Vlasova

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: avvla@mail.ru
ORCID iD: 0000-0002-7677-1544
SPIN-code: 8802-7325

Can. Sci. (Med.)

Russian Federation, Moscow

References

  1. RNC Pharma представляет информацию относительно активности ввоза ЛП в Россию по итогам декабря 2022 г. [RNC Pharma presents information regarding the activity of drug imports into Russia based on the results of December 2022. (In Russ.)]. URL: https://rncph.ru/news/03_02_2023.
  2. Ассоциация туроператоров. [Association of Tour Operators. (In Russ.)]. URL: https://www.atorus.ru/node/51582.
  3. Харина И.А., Джупарова И.А. Оценка доступности пероральных лекарственных препаратов для лечения сахарного диабета 2-го типа в аптечных организациях г. Новосибирска. J Siber Med Sci. 2022;6(3):15–22. [Kharina I.A., Dzhuparova I.A. Assessment of the availability of oral medications for the treatment of type 2 diabetes mellitus in pharmacies in Novosibirsk. J Siber Med Sci. 2022;6(3):15–22. (In Russ.)].
  4. Grover N., Fick M. EU must do more to tackle antibiotic shortages, say patient groups. Reuters 24.01.2023. URL: https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-must-do-more-tackle-medicine-shortages-patient-orgs-2023-01-24.
  5. Фармацевтический вестник 29.07.2021. [Farmatsevticheskiy vestnik 29.07.2021. (In Russ.)]. URL: https://pharmvestnik.ru/content/news/Minzdrav-otozval-registraciu-dvuh-preparatov-iz-za-nepredstavlennyh- dokumentov.html.
  6. Forbs 18/07/2023. URL: https://www.forbes.ru/biznes/493031-finskaa-farmkompania-orion-pharma-usla-iz-rossii.
  7. Смехова И.Е., Ладутько Ю.М., Калинина О.В. Экстемпоральное изготовление лекарственных препаратов: проблемы и решения. Вестник фармации. 2021;1(91):48–52. [Smekhova I.E., Ladutko Yu.M., Kalinina O.V. Extemporaneous production of medicinal products: problems and solutions. Vestnik farmatsii. 2021;1(91):48–52. (In Russ.)]. doi: 10.52540/2074-9457.2021.1.48.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies